Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Raffles Medical Group ( (SG:BSL) ) is now available.
Raffles Medical Group held its 37th annual general meeting in Singapore, where shareholders reviewed the audited financial statements for the year ended 31 December 2025 and confirmed the group’s financial performance. The meeting also endorsed a one-tier tax-exempt final dividend of 3.0 Singapore cents per share, signalling continued capital returns to investors.
Shareholders approved directors’ fees, including a mix of cash and share options, and re-elected key board members Dr Loo Choon Yong and Mr Olivier Lim, reinforcing leadership continuity. They also appointed Ernst & Young as new auditors in place of KPMG and renewed mandates to issue shares, operate share-based incentive schemes, conduct share buybacks and support a scrip dividend scheme, providing management with flexibility in capital management and employee alignment.
The most recent analyst rating on (SG:BSL) stock is a Hold with a S$1.02 price target. To see the full list of analyst forecasts on Raffles Medical Group stock, see the SG:BSL Stock Forecast page.
More about Raffles Medical Group
Raffles Medical Group is a Singapore-based healthcare provider operating hospitals, clinics and related medical services in the region. The group serves both local and international patients, focusing on integrated healthcare delivery and corporate and individual healthcare solutions within the broader Asian medical services market.
Average Trading Volume: 1,815,439
Technical Sentiment Signal: Hold
Current Market Cap: S$1.82B
See more data about BSL stock on TipRanks’ Stock Analysis page.